Holdouts from the pharmaceutical giant's $10 billion settlement offer aim to question the legitimacy of the bankruptcy altogether.
Ossowski: A narrow window for justice in…
Holdouts from the pharmaceutical giant's $10 billion settlement offer aim to question the legitimacy of the bankruptcy altogether.